+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Iron metabolism in rhEPO-treated hemodialysis patients

Iron metabolism in rhEPO-treated hemodialysis patients

Clinical Nephrology 53(1 Suppl): S65-S68

A number of factors have been shown to limit the response to recombinant human erythropoietin (rhEPO). One major factor appears to be an inadequate iron supply to the bone marrow. Erythropoiesis is dependent upon a continuous supply of iron to the bone marrow. The rate at which iron can be drawn from existing stores may easily limit the rate of delivery for hemoglobin synthesis. This may result in "functional iron deficiency" which is distinct from "absolute iron deficiency" caused by depletion of iron stores. At present there are three main parameters available to clinicians wishing to monitor iron status in their patients: serum ferritin and transferrin saturation (TFS), which are indirect measurements, and the percentage of hypochromic red cells, which directly reflects marrow iron status. Ferritin levels should be measured before starting rhEPO therapy to ensure adequate iron stores (> 200 microg/l), and when patients move from the correction phase to the maintenance phase of therapy (have stores become depleted during the correction phase?). In addition, ferritin levels can give an indication of iron overload following excess parenteral iron administration. The TFS represents a balance between iron supply by the stores and demand by bone marrow. A saturation below 20% probably indicates iron-deficient erythropoiesis. However, this is an indirect measure of marrow iron supply and wide fluctuations have been observed when determined at different time points. The percentage of hypochromic red blood cells is measured by flow cytometry and a hypochromic subpopulation of more than 10% (normal percentage > 2.5%) indicates iron-deficient erythropoiesis. However, not all departments have access to the required equipment. The aim of iron supplementation is to provide sufficient iron for the correction phase and replace iron losses (1,500 - 3,000 mg/year in hemodialysis patients) during the maintenance phase of rhEPO therapy. This amounts to a daily iron need in the range of 5-7 mg, which is well above the normal dietary intake and absorptive capacity of the human intestine. Therefore there is a need for intravenous iron, in particular when the patient ha absolute or functional iron deficiency, is in tolerant of oral iron, or is not complying we with the oral regimen.

(PDF emailed within 1 workday: $29.90)

Accession: 010885256

Download citation: RISBibTeXText

PMID: 10746809

Related references

Circulating cell-free DNA levels in hemodialysis patients and its association with inflammation, iron metabolism, and rhEPO doses. Hemodialysis International. International Symposium on Home Hemodialysis 17(4): 664-667, 2014

Regulation of Hepcidin-25 by Short- and Long-Acting rhEPO May Be Dependent on Ferritin and Predict the Response to rhEPO in Hemodialysis Patients. Nephron Extra 4(1): 55-63, 2014

Correlation of amino acid metabolism during rhEPO therapy in hemodialysis patients. Nephron 69(2): 196, 1995

Role of prohepcidin, inflammatory markers and iron status in resistance to rhEPO therapy in hemodialysis patients. American Journal of Nephrology 28(4): 677-683, 2008

Influence of rhEPO therapy on the protein metabolism of hemodialysis patients with terminal renal insufficiency. Contributions to Nephrology 76: 250-256, 1989

The influence of rhepo therapy on the protein metabolism of terminal kidney failure hemodialysis patients. Wolfram, G , J Eckart And M Adolph (Ed ) Beitraege Zur Infusionstherapie, Band 25 Kuenstliche Ernaehrung 1989: Indikationen, Monitoring, Komplikationen, Therapie, Indirekte Kalorimetrie, Stabile Isotope; (Contributions to Infusion Therapy, Vol 25 Artificial Feeding: Indications, Monitoring, Complications, Treatment, Indirect Calorimetry, Stable Isotopes); Eighth Joint Convention Of The German Work Group For Artificial Feeding And The Austrian Work Group For Clinical Nutrition, Augsbu, 1990

Correction of amino acid metabolism during rhEPO therapy in hemodialysis patients results from a better oxygen availability. Nephron 69(2): 196-197, 1995

Oxidative stress and non transferrin bound iron in hemodialysis patients treated with intra-venous polymaltose iron. Journal of the American Society of Nephrology 13(Program and Abstracts Issue): 583A, September, 2002

New parameters in iron metabolism and functional iron deficiency in patients on maintenance hemodialysis. Polskie Archiwum Medycyny Wewnetrznej 122(11): 537-542, 2013

Changes in red blood cell density distribution in hemodialysis patients effect of rhepo. Kidney International 37(1): 300, 1990

Effects of recombinant human erythropoietin rhepo on t lymphocyte subsets in hemodialysis patients hd pts. European Journal of Clinical Investigation 20(2 PART 2): A54, 1990

Biochemical pattern of red blood cells rbc of hemodialysis hd patients effects of erythropoietin rhepo therapy. Journal of the American Society of Nephrology 2(3): 379, 1991

Lipid peroxidation and vitamin E in red blood cells and plasma in hemodialysis patients under rhEPO treatment. Artificial Organs. : 436-439, 1995

Apoptosis of peripheral CD4(+) T-lymphocytes in end-stage renal disease patients under hemodialysis and rhEPO therapies. Renal Failure 33(2): 138-143, 2011